This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $185.09 in the latest trading session, marking a +0.44% move from the prior day.
Top Analyst Reports for Disney, Adobe & Wells Fargo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Adobe Inc. (ADBE), and Wells Fargo & Company (WFC).
5 Top Ranked Stocks on Sale Right Now
by Tracey Ryniec
These stocks are disconnected from their earnings outlook as the analysts remain bullish but the Street is bearish.
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $188.30 in the latest trading session, marking a +0.64% move from the prior day.
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
by Zacks Equity Research
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
by Zacks Equity Research
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
by Zacks Equity Research
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
by Zacks Equity Research
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $188.57 in the latest trading session, marking a +0.26% move from the prior day.
What Makes Vertex (VRTX) a New Strong Buy Stock
by Zacks Equity Research
Vertex (VRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma
by Zacks Equity Research
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review
by Zacks Equity Research
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
The Zacks Analyst Blog Highlights: Regeneron, Vertex Pharmaceuticals and West Pharmaceutical Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Vertex Pharmaceuticals and West Pharmaceutical Services
A Short Trading Week: Global Week Ahead
by John Blank
The trading week is shorted to four days for stocks listed solely in the U.S. In turn, this Global Week Ahead looks to be dominated by non-U.S. events.